Dupilumab has an additional benefit in treatment of chronic rhinosinusitis with nasal polyps

xlomafota13 shared this article with you from Inoreader Dupilumab has an additional benefit in treatment of chronic rhinosinusitis with nasal polyps Via hno HNO. 2021 Mar 18. doi: 10.1007/s00106-021-01018-z. Online ahead of print. ABSTRACT BACKGROUND: For patients with severe chronic rhinosinusitis with nasal polyps (CRSwNP) which cannot be controlled by continuous therapy with intranasal corticosteroids (INCS) and systemic corticosteroids and/or surgical treatment, there were no approved curative options for a long time. For CRSwNP treatment with T2-addressing biologics is possible. On October 24, 2019, the European Commission granted extended approval for dupilumab as the first biological agent for treatment of insufficiently controlled severe CRSwNP. The Federal Joint Committee (G‑BA) evaluates the benefits of reimbursable drugs with new active ingredients. This includes assessment of the additional benefit and its therapeutic relevance. METHODS: A meta-analysis was performed using individual patient data based on two phase III studies. Both studies examined the safety and efficacy of dupilumab as an add-on therapy to INCS for treatment of CRSwNP in adults inadequately controlled with systemic corticosteroids and/or surgery compared to INCS alone. RESULTS: Based on the present data, the G‑BA decided that there is an indication of a considerable additional benefit of dupilumab compared to mometasone furoate. CONCLUSION: For patients with severe CRSwNP inadequately controlled with INCS and systemic corticosteroids and/or surgery, there is an indication of a considerable additional be nefit for the administration of dupilumab as an add-on therapy to INCS compared to mometasone furoate alone. PMID:33738558 | DOI:10.1007/s00106-021-01018-z View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.